惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

D
DataBreaches.Net
B
Blog
博客园_首页
C
Check Point Blog
Microsoft Security Blog
Microsoft Security Blog
MyScale Blog
MyScale Blog
P
Proofpoint News Feed
Engineering at Meta
Engineering at Meta
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
B
Blog RSS Feed
M
MIT News - Artificial intelligence
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
WordPress大学
WordPress大学
宝玉的分享
宝玉的分享
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
The Cloudflare Blog
量子位
V
V2EX
Y
Y Combinator Blog
Hugging Face - Blog
Hugging Face - Blog
Martin Fowler
Martin Fowler
Recent Announcements
Recent Announcements
I
InfoQ
博客园 - 【当耐特】

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Takeda Pharmaceutical Company Limited (TAK) Q4 FY2025 Ear...
2026-05-21 · via All Articles on Seeking Alpha

Takeda Pharmaceutical Company Limited (TAK) Q4 FY2025 Earnings Call May 13, 2026 6:00 AM EDT

Company Participants

Christopher David O'Reilly - Global Head of Investor Relations & Global Finance
Christophe Weber - President, CEO & Representative Director
Julie Kim - Interim Head of Global Portfolio Division
Milano Furuta - CFO & Director
Andrew Plump - President of Research & Development and Representative Director
Rhonda Pacheco - President of U.S. Business Unit & U.S. Country Head

Conference Call Participants

Shinichiro Muraoka - Morgan Stanley, Research Division
Hidemaru Yamaguchi - Citigroup Inc., Research Division
Michael Nedelcovych - TD Cowen, Research Division
Matsubara - Nomura Securities Co. Ltd., Research Division
Stephen Barker - Jefferies LLC, Research Division
Tony Ren - Macquarie Research
Miki Sogi - Bernstein Institutional Services LLC, Research Division

Presentation

Christopher David O'Reilly
Global Head of Investor Relations & Global Finance

[Audio Gap] [Operator Instructions]

[Interpreted] Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings. And please also refer to the important notice on Page 2. We may also refer to non-IFRS financial numbers. For the definition and reconciliations, please refer to the appendix in the presentation.

Now, let's start today's presentation. President and CEO, Christophe Weber; CEO-Elect, Julie Kim; Chief Financial Officer, Milano Furuta; R&D President, Andy Plump. They will be presenting followed by Q&A session. Let's start.

Christophe Weber
President, CEO & Representative Director

Thank you, Chris, and good morning, good afternoon and good evening, everyone. Thank you for joining us today for Takeda year-end earnings call. Today will be my last earnings call as President and CEO of Takeda. It has been a real privilege